Corynoline enhances sorafenib sensitivity in hepatocellular carcinoma via NOS3-mediated ROS production.

ABSTRACT:

Background

The clinical application of sorafenib (Sora) in advanced hepatocellular carcinoma (HCC) is greatly limited due to its moderate efficacy and acquired resistance. Combination therapy with other agents holds promise to improve therapeutic efficacy.

Purpose

Our study aimed to screen alkaloids exerting synergistic anticancer effects with low-dose Sora in HCC treatment and underlie its molecular mechanisms.

Methods

CCK-8 assay was used to evaluate the inhibition rates of Sora combined with alkaloids. The most likely binding targets were predicted by molecular docking simulations, and further verified through CETSA and DARTS. ROS levels were measured by flow cytometry. IL-18 levels were detected using ELISA. Nude mouse xenograft models were employed to validate th

SUBMITTER: Yi Q 

PROVIDER: S-EPMC12616971 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature